Bionomics Free Cash Flow 2022-2024 | NEUP
Bionomics free cash flow from 2022 to 2024. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
| Bionomics Annual Free Cash Flow |
| 2024 |
-14.68 |
| 2023 |
-14.64 |
| 2022 |
-15.66 |
| 2021 |
-5.61 |
| Bionomics Quarterly Free Cash Flow |
| 2024-09-30 |
-4.43 |
| 2024-06-30 |
|
| 2023-09-30 |
-4.43 |
| 2023-06-30 |
|
| 2022-12-31 |
|
| 2022-06-30 |
|
| 2021-06-30 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.007B |
$0.000B |
|
Bionomics Limited is a clinical-stage biopharmaceutical developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders. Bionomics Limited is based in ADELAIDE, Australia.
|
| Stock Name |
Country |
Market Cap |
PE Ratio |
| Kidpik (PIKM) |
United States |
$0.000B |
0.00 |
